-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest announcement on the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, the JNJ-53718678 oral suspension developed by Johnson & Johnson's Janssen company is intended to be included in the breakthrough treatment category.
Screenshot source: CDE official website
RSV is the main cause of pneumonia and bronchiolitis in young children and the elderly.
As a new oral inhibitor of RSV fusion protein, JNJ-53718678 can specifically target and bind to the fusion protein on the surface of the virus, inhibit RSV fusion protein-mediated fusion with the host cell membrane, and prevent the virus from entering.
According to the information on the ClinicalTrials.
At present, Janssen is carrying out a number of clinical trials on JNJ-53718678: one of them is a randomized, double-blind, placebo-controlled phase 2 clinical trial, which aims to evaluate the hematopoiesis of JNJ-53718678 in adults and adolescents infected with RSV in the upper respiratory tract.
